Elicio Therapeutics, Inc.
ELTXHealthcare|Biotechnology|US
$1.51
+0.11 (+7.86%)
DCF Value
$0.23
Tangible Book / Share
$0.72
Cash / Share
$1.18
Financials
Financial Snapshot
Market Cap
$28.8M
Enterprise Value
$4.7M
Revenue (TTM)
$0.00
Net Income (TTM)
-$35.7M
Cash & Investments
$30.9M
Net Cash
$24.1M
Free Cash Flow (TTM)
-$37.0M
Operating CF (TTM)
-$37.0M
Debt/Equity
0.36
Cash Runway & Burn Rate
Cash on Hand
$30.9M
Quarterly Burn
$9.2M
Monthly Burn
$3.1M
Est. Runway
~3.3 quarters
| Metric | Trend | 2012 | 2013 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $1.4M | $2.1M | $25.5M | $5.6M | $34.6M | $88.8M | $7.8M | $12.9M | $17.6M | $18.6M | $30.9M | |
| Operating Cash Flow | $1.1M | $1.9M | -$8.0M | -$24.6M | -$22.9M | -$23.9M | -$22.2M | -$32.7M | -$37.1M | -$37.0M | -$37.0M | |
| Free Cash Flow | $1.0M | $1.9M | -$8.0M | -$24.8M | -$22.9M | -$24.5M | -$22.8M | -$32.8M | -$37.2M | -$37.0M | -$37.0M | |
| Capital Expenditure | -$47.7K | -$17.6K | $0.00 | -$242.0K | -$41.0K | -$525.4K | -$654.0K | -$66.0K | -$87.0K | -$16.0K | -$16.0K | |
| Financing Cash Flow | -$429.2K | -$1.2M | $31.7M | $4.9M | $52.4M | $19.4M | $21.2M | $38.6M | $42.3M | $36.7M | $47.2M |
R&D Spending
R&D (TTM)
$23.5M
R&D Intensity
—
R&D Growth vs Prior
-5.7%
| Metric | Trend | 2012 | 2013 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.3M | $6.6M | $4.0M | $1.5M | $2.9M | $28.3M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $0.00 | $196.0K | $9.2M | $29.8M | $38.9M | $48.6M | $17.0M | $22.7M | $33.7M | $24.9M | $23.5M | |
| R&D % of Revenue | 0.0% | 3.0% | 227.1% | 2003.2% | 1350.0% | 171.7% | — | — | — | — | — | |
| SG&A | $4.0M | $3.6M | $8.8M | $9.2M | $17.5M | $17.8M | $5.6M | $11.9M | $11.3M | $12.8M | $14.8M |
Income Statement
| Metric | Trend | 2012 | 2013 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.3M | $6.6M | $4.0M | $1.5M | $2.9M | $28.3M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $3.7M | $3.2M | $380.0K | $1.1M | $1.8M | $1.2M | $1.1M | $1.2M | $1.2M | $1.1M | $289.0K | |
| Gross Profit | $3.6M | $3.4M | $3.6M | $351.0K | $1.1M | $27.1M | -$1.1M | -$1.2M | -$1.2M | -$1.1M | -$289.0K | |
| R&D | $0.00 | $196.0K | $9.2M | $29.8M | $38.9M | $48.6M | $17.0M | $22.7M | $33.7M | $24.9M | $23.5M | |
| SG&A | $4.0M | $3.6M | $8.8M | $9.2M | $17.5M | $17.8M | $5.6M | $11.9M | $11.3M | $12.8M | $14.8M | |
| Operating Income | -$419.2K | -$397.8K | -$14.3M | -$38.6M | -$55.3M | -$39.3M | -$23.7M | -$35.7M | -$45.0M | -$37.7M | -$38.3M | |
| Interest Expense | $307.4K | $300.4K | $0.00 | $0.00 | $8.8M | $876.4K | $3.6M | $1.1M | $455.0K | $1.1M | $741.0K | |
| Pretax Income | $1.2M | $1.7M | -$20.0M | -$40.7M | -$80.1M | -$54.6M | -$28.2M | -$35.2M | -$51.9M | -$39.6M | -$35.8M | |
| Net Income | $307.3K | $632.2K | -$20.0M | -$40.7M | -$80.1M | -$26.4M | -$28.2M | -$35.2M | -$51.9M | -$39.6M | -$35.7M | |
| EPS (Diluted) | 50.21 | 103.31 | -6.79 | -1.50 | -1.93 | -19.32 | -9.10 | -6.96 | -4.25 | -2.58 | -1.83 | |
| EBITDA | $2.0M | $62.5K | -$14.3M | -$40.2M | -$70.6M | -$52.5M | -$23.6M | -$33.0M | -$50.3M | -$37.3M | -$39.3M | |
| Shares Out. (M) | 0.01 | 0.01 | 2.95 | 8.15 | 8.15 | 3.20 | 3.10 | 5.06 | 12.20 | 15.31 | 26.29 |
Balance Sheet
| Metric | Trend | 2012 | 2013 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.4M | $2.1M | $25.5M | $5.6M | $34.6M | $88.8M | $7.8M | $12.9M | $17.6M | $18.6M | $30.9M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $2.1M | $2.6M | $25.7M | $6.1M | $40.3M | $91.2M | $10.7M | $16.3M | $20.7M | $19.3M | $34.0M | |
| Total Assets | $11.0M | $11.1M | $26.6M | $11.9M | $47.3M | $96.5M | $22.7M | $27.1M | $28.2M | $25.9M | $39.6M | |
| Total Current Liabilities | $1.1M | $1.1M | $7.4M | $26.6M | $107.4M | $11.3M | $6.9M | $9.8M | $11.5M | $8.1M | $9.9M | |
| Long-Term Debt | $5.3M | $5.2M | $0.00 | $0.00 | $635.0K | $0.00 | $0.00 | $0.00 | $20.0M | $9.4M | $3.3M | |
| Total Liabilities | $6.8M | $6.6M | $7.7M | $30.5M | $137.8M | $15.0M | $13.7M | $15.8M | $39.5M | $24.2M | $20.7M | |
| Stockholders' Equity | $1.7M | $2.3M | $18.9M | -$18.6M | -$90.4M | $81.5M | $8.9M | $11.4M | -$11.3M | $1.6M | $18.9M | |
| Retained Earnings | $1.7M | $2.3M | -$39.8M | -$80.5M | -$160.6M | -$215.1M | -$107.0M | -$142.2M | -$194.1M | -$233.7M | -$261.7M |
Cash Flow Statement
| Metric | Trend | 2012 | 2013 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.1M | $1.9M | -$8.0M | -$24.6M | -$22.9M | -$23.9M | -$22.2M | -$32.7M | -$37.1M | -$37.0M | -$37.0M | |
| Capital Expenditure | -$47.7K | -$17.6K | $0.00 | -$242.0K | -$41.0K | -$525.4K | -$654.0K | -$66.0K | -$87.0K | -$16.0K | -$16.0K | |
| Free Cash Flow | $1.0M | $1.9M | -$8.0M | -$24.8M | -$22.9M | -$24.5M | -$22.8M | -$32.8M | -$37.2M | -$37.0M | -$37.0M | |
| Investing Cash Flow | -$47.7K | -$67.6K | $0.00 | -$242.0K | -$41.0K | -$525.4K | -$654.0K | -$32.0K | -$84.0K | -$16.0K | -$16.0K | |
| Financing Cash Flow | -$429.2K | -$1.2M | $31.7M | $4.9M | $52.4M | $19.4M | $21.2M | $38.6M | $42.3M | $36.7M | $47.2M | |
| Issuance of Stock | $0.00 | $0.00 | $28.6M | $0.00 | $20.3M | $101.4K | $82.0K | $7.1M | $5.6M | $26.8M | $43.4M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | -$375.0K | -$36.0K | $0.00 | $0.00 | -$150.0K | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $3.1M | $5.3M | $32.1M | $14.0M | $0.00 | $10.0M | $19.7M | $9.9M | -$9.9M | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $617.8K | $579.0K | $1.2M | $1.5M | $2.7M | $3.7M | |
| Net Change in Cash | $588.2K | $652.8K | $23.5M | -$19.9M | $29.0M | -$5.1M | -$81.0M | $5.9M | $5.2M | -$233.0K | $10.1M |
Dilution Tracker
Shares outstanding grew 87.9% over 5 years — significant dilution
Shares Outstanding
19M
5-Year Share Growth
+87.9%
Stock Issuance (TTM)
$43.4M
| Metric | Trend | 2012 | 2013 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.01 | 0.01 | 2.95 | 8.15 | 8.15 | 3.20 | 3.10 | 5.06 | 12.20 | 15.31 | 26.29 | |
| Change vs Prior % | — | 0.0% | 48077.3% | 176.4% | 0.0% | -60.7% | -3.1% | 63.1% | 141.3% | 25.5% | 71.7% | |
| Stock Issuance | $0.00 | $0.00 | $28.6M | $0.00 | $20.3M | $101.4K | $82.0K | $7.1M | $5.6M | $26.8M | $43.4M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | -$375.0K | -$36.0K | $0.00 | $0.00 | -$150.0K | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $617.8K | $579.0K | $1.2M | $1.5M | $2.7M | $3.7M |
Margins & Profitability
| Metric | Trend | 2012 | 2013 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 49.7% | 51.8% | 90.6% | 23.6% | 36.9% | 95.6% | — | — | — | — | — | |
| Operating Margin % | -5.7% | -6.0% | -356.0% | -2595.2% | -1919.2% | -138.8% | — | — | — | — | — | |
| Net Margin % | 4.2% | 9.6% | -497.0% | -2734.2% | -2781.5% | -93.2% | — | — | — | — | — | |
| EBITDA Margin % | 26.9% | 1.0% | -355.9% | -2700.9% | -2452.5% | -185.3% | — | — | — | — | — | |
| FCF Margin % | 13.9% | 28.5% | -199.1% | -1669.9% | -796.1% | -86.4% | — | — | — | — | — | |
| ROE % | 18.0% | 27.0% | -105.9% | 218.8% | 88.6% | -32.4% | -316.4% | -309.5% | 458.8% | -2418.8% | -529.7% | |
| ROA % | 2.8% | 5.7% | -75.2% | -342.1% | -169.2% | -27.4% | -124.5% | -129.7% | -184.2% | -153.0% | -90.3% | |
| ROIC % | -3.5% | -2.9% | -74.4% | 494.2% | -270.2% | -45.6% | -143.9% | -195.3% | -256.2% | -201.0% | -115.1% | |
| R&D / Revenue % | 0.0% | 3.0% | 227.1% | 2003.2% | 1350.0% | 171.7% | — | — | — | — | — |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2012 | 2013 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | -9.8% | 0.0% | -63.1% | 93.7% | 883.1% | -100.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | -6.0% | 0.0% | -90.4% | 202.6% | 2449.7% | -103.9% | -10.7% | -0.7% | 4.2% | |
| Operating Income | 0.0% | 5.1% | 0.0% | -169.1% | -43.2% | 28.9% | 39.6% | -50.6% | -25.9% | 16.2% | |
| Net Income | 0.0% | 105.7% | 0.0% | -103.0% | -97.0% | 67.0% | -6.8% | -24.8% | -47.5% | 23.8% | |
| EPS (Diluted) | 0.0% | 105.8% | 0.0% | 77.9% | -28.7% | -901.0% | 52.9% | 23.5% | 38.9% | 39.3% | |
| Operating Cash Flow | 0.0% | 77.7% | 0.0% | -206.6% | 6.9% | -4.6% | 7.4% | -47.4% | -13.4% | 0.3% | |
| Free Cash Flow | 0.0% | 84.3% | 0.0% | -209.6% | 7.7% | -6.7% | 6.7% | -43.5% | -13.4% | 0.5% | |
| R&D Expense | 0.0% | 0.0% | 0.0% | 225.5% | 30.5% | 25.0% | -64.9% | 33.0% | 48.4% | -26.0% | |
| SG&A Expense | 0.0% | -10.7% | 0.0% | 3.6% | 90.7% | 1.8% | -68.3% | 111.3% | -4.8% | 13.1% | |
| Total Assets | 0.0% | 0.3% | 0.0% | -55.4% | 298.3% | 103.8% | -76.5% | 19.8% | 3.8% | -8.2% | |
| Book Value / Share | 0.0% | 5.2% | 0.0% | -135.6% | -386.7% | 329.5% | -88.7% | -21.8% | -141.2% | 111.5% | |
| Debt | 0.0% | -2.1% | 0.0% | 0.0% | 689.0% | -94.5% | 60.5% | -7.5% | 276.5% | -44.3% | |
| Diluted Shares | 0.0% | 0.0% | 0.0% | 176.4% | 0.0% | -60.7% | -3.1% | 63.1% | 141.3% | 25.5% |
Valuation
P/E (TTM)At Loss
P/S0.00
10Y Low / Med / High0.00 / 4.31 / 32.28
P/B2.11
10Y Low / Med / High0.02 / 0.92 / 74.50
EV/EBITDAAt Loss
10Y Low / Med / High0.57 / 2.07 / 52.82
EV/Revenue0.00
10Y Low / Med / High0.50 / 34.18 / 35.78
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$0.23
Tangible Book / Share
$0.72
Net Current Assets / Share
$0.70
Graham Net-Net
$0.39
Cash / Share
$1.18
| Metric | Trend | 2012 | 2013 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | 0.12 | 0.06 | -0.87 | -3.93 | -3.05 | -0.30 | -0.65 | -1.20 | -1.20 | -3.09 | -0.83 | |
| P/S Ratio | 0.00 | 0.01 | 4.31 | 32.28 | 16.67 | 0.67 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 0.02 | 0.02 | 0.92 | -2.58 | -0.53 | 0.23 | 2.05 | 3.71 | -5.50 | 74.50 | 2.11 | |
| EV/EBITDA | 2.07 | 52.82 | 0.57 | -1.32 | -1.39 | 1.24 | -0.76 | -1.10 | -1.41 | -3.16 | -0.12 | |
| EV/Revenue | 0.56 | 0.50 | -2.02 | 35.78 | 34.18 | -2.30 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-11.04
Distress
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $20.0M | $0.00 | $0.00 |
| Net Income | -$29.3M | -$25.9M | -$18.1M |
| EPS | $-1.88 | $-1.69 | $-1.18 |
| # Analysts (EPS) | 2 | 3 | 1 |